Ocugen获得巴哈马监管机构临时批准OCU 400已获得批准和优先指定;该公司将通过BEP供应OCU 400，目标是在90天内治疗首例RP患者

2026-09-25 19:13

Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP) within 90 days, following full approval by the Longevity and Regenerative Therapies Board (LARTA Board)
In partnership with the LARTA Board, Ocugen intends to address global access and unmet need through commercial pricing evidenced with cost-effectiveness for a one-time broad treatment of RP
A novel modifier gene therapy for RP, OCU400 is advancing through Phase 3, with topline data expected in 1Q 2027 and a Biologics License Application submission planned for 2Q 2027